HU227198B1 - Pharmaceutical composition for emergency contraception containing levonorgestrel - Google Patents
Pharmaceutical composition for emergency contraception containing levonorgestrel Download PDFInfo
- Publication number
- HU227198B1 HU227198B1 HU0105173A HUP0105173A HU227198B1 HU 227198 B1 HU227198 B1 HU 227198B1 HU 0105173 A HU0105173 A HU 0105173A HU P0105173 A HUP0105173 A HU P0105173A HU 227198 B1 HU227198 B1 HU 227198B1
- Authority
- HU
- Hungary
- Prior art keywords
- levonorgestrel
- pharmaceutical composition
- hours
- administration
- contraception
- Prior art date
Links
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 title claims description 35
- 229960004400 levonorgestrel Drugs 0.000 title claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000035935 pregnancy Effects 0.000 claims description 6
- 230000001568 sexual effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 230000002254 contraceptive effect Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000003433 contraceptive agent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 239000008119 colloidal silica Substances 0.000 description 5
- 229960002568 ethinylestradiol Drugs 0.000 description 5
- 229960001021 lactose monohydrate Drugs 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 230000002513 anti-ovulatory effect Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940038565 levonorgestrel 1.5 mg Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000008385 outer phase Substances 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000019100 sperm motility Effects 0.000 description 2
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010049872 Breast discomfort Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000031271 Unwanted pregnancy Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940030877 levonorgestrel 0.75 mg Drugs 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (33)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105173A HU227198B1 (en) | 2001-11-27 | 2001-11-27 | Pharmaceutical composition for emergency contraception containing levonorgestrel |
| SI200230132T SI1448207T1 (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| ES02783334T ES2239727T3 (es) | 2001-11-27 | 2002-11-26 | Regimen de dosificacion y composicion farmaceutica para anticoncepcion de emergencia. |
| YUP-42/04A RS50768B (sr) | 2001-11-27 | 2002-11-26 | Režim doziranja i farmaceutska formulacija za urgentnu zaštitu |
| NZ530056A NZ530056A (en) | 2001-11-27 | 2002-11-26 | Single administration of 1.5 mg levonorgestrel increases compliance and decreases possibility of incorrect use of this post-coital contraceptive |
| JP2003546899A JP2005516904A (ja) | 2001-11-27 | 2002-11-26 | 緊急避妊のための薬学的組成物およびその用量処方 |
| PL369520A PL206010B1 (pl) | 2001-11-27 | 2002-11-26 | Środek farmaceutyczny do antykoncepcji doraźnej zawierający lewonorgestrel i zastosowanie lewonorgestrelu |
| AT02783334T ATE293978T1 (de) | 2001-11-27 | 2002-11-26 | Behandlungsverfahren und pharmazeutische zusammensetzung zur notfall-empfängnisverhütung |
| PT02783334T PT1448207E (pt) | 2001-11-27 | 2002-11-26 | Composicao farmaceutica e regime de dosagem para a contracepcao de emergencia |
| CA2450359A CA2450359C (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| HR20040584 HRP20040584B1 (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| DK02783334T DK1448207T3 (da) | 2001-11-27 | 2002-11-26 | Doseringsplan og farmaceutisk sammensætning af nödprævention |
| UA20040504015A UA79942C2 (en) | 2001-11-27 | 2002-11-26 | Levonorgestrel pharmaceutical composition and use thereof for emergency contraception |
| OA1200400148A OA12730A (fr) | 2001-11-27 | 2002-11-26 | Régime de dosage et composition pharmaceutique pour contraception d'urgence. |
| CNA028137523A CN1551774A (zh) | 2001-11-27 | 2002-11-26 | 紧急避孕药物剂量方案和药物组合物 |
| EP02783334A EP1448207B1 (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| KR1020047002069A KR100908161B1 (ko) | 2001-11-27 | 2002-11-26 | 응급피임용 투약방법 및 약제학적 조성물 |
| APAP/P/2004/003046A AP1849A (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| IL15939402A IL159394A0 (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| DE60203929T DE60203929T2 (de) | 2001-11-27 | 2002-11-26 | Behandlungsverfahren und pharmazeutische zusammensetzung zur notfall-empfängnisverhütung |
| MXPA04005104A MXPA04005104A (es) | 2001-11-27 | 2002-11-26 | Regimen de dosificacion y composicion farmaceutica para anticoncepcion de emergencia. |
| AU2002347401A AU2002347401A1 (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| PCT/HU2002/000129 WO2003045397A1 (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| EA200400731A EA006545B1 (ru) | 2001-11-27 | 2002-11-26 | Единичная дозированная форма фармацевтической композиции для экстренной контрацепции и способы её получения и применения |
| GE5567A GEP20063882B (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| BR0210595-0A BR0210595A (pt) | 2001-11-27 | 2002-11-26 | Regime de dosagem e composição farmacêutica para contracepção de emergência |
| IS7065A IS2691B (is) | 2001-11-27 | 2003-12-05 | Áætlun um lyfjaskammta og lyfjasamsetningar til getnaðarvarnar í neyð |
| TNP2004000048A TNSN04048A1 (en) | 2001-11-27 | 2004-03-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| NO20041607A NO333984B1 (no) | 2001-11-27 | 2004-04-20 | Farmasøytisk preparat for nødprevensjon og anvendelse derav. |
| MA27643A MA27076A1 (fr) | 2001-11-27 | 2004-04-21 | Regime de dosage et composition pharmaceutique pour contraception d'urgence |
| ZA2004/04114A ZA200404114B (en) | 2001-11-27 | 2004-05-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
| EC2004005171A ECSP045171A (es) | 2001-11-27 | 2004-06-25 | Régimen de dosificación y composición farmacéutica para anticoncepción de emergencia |
| US10/495,923 US20050288264A2 (en) | 2001-11-27 | 2004-10-05 | Dosage Regimen and Pharmaceutical Composition for Emergency Contraception |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105173A HU227198B1 (en) | 2001-11-27 | 2001-11-27 | Pharmaceutical composition for emergency contraception containing levonorgestrel |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| HUP0105173D0 HUP0105173D0 (en) | 2002-02-28 |
| HUP0105173A2 HUP0105173A2 (hu) | 2003-08-28 |
| HUP0105173A3 HUP0105173A3 (en) | 2004-03-29 |
| HU227198B1 true HU227198B1 (en) | 2010-10-28 |
Family
ID=89998939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0105173A HU227198B1 (en) | 2001-11-27 | 2001-11-27 | Pharmaceutical composition for emergency contraception containing levonorgestrel |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20050288264A2 (https=) |
| EP (1) | EP1448207B1 (https=) |
| JP (1) | JP2005516904A (https=) |
| KR (1) | KR100908161B1 (https=) |
| CN (1) | CN1551774A (https=) |
| AP (1) | AP1849A (https=) |
| AT (1) | ATE293978T1 (https=) |
| AU (1) | AU2002347401A1 (https=) |
| BR (1) | BR0210595A (https=) |
| CA (1) | CA2450359C (https=) |
| DE (1) | DE60203929T2 (https=) |
| DK (1) | DK1448207T3 (https=) |
| EA (1) | EA006545B1 (https=) |
| EC (1) | ECSP045171A (https=) |
| ES (1) | ES2239727T3 (https=) |
| GE (1) | GEP20063882B (https=) |
| HR (1) | HRP20040584B1 (https=) |
| HU (1) | HU227198B1 (https=) |
| IL (1) | IL159394A0 (https=) |
| IS (1) | IS2691B (https=) |
| MA (1) | MA27076A1 (https=) |
| MX (1) | MXPA04005104A (https=) |
| NO (1) | NO333984B1 (https=) |
| NZ (1) | NZ530056A (https=) |
| OA (1) | OA12730A (https=) |
| PL (1) | PL206010B1 (https=) |
| PT (1) | PT1448207E (https=) |
| RS (1) | RS50768B (https=) |
| SI (1) | SI1448207T1 (https=) |
| TN (1) | TNSN04048A1 (https=) |
| UA (1) | UA79942C2 (https=) |
| WO (1) | WO2003045397A1 (https=) |
| ZA (1) | ZA200404114B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008079245A2 (en) * | 2006-12-20 | 2008-07-03 | Duramed Pharmaceuticals, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
| BRPI0819571A2 (pt) * | 2007-12-20 | 2019-09-24 | Teva Womenss Health Inc | "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica" |
| US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
| EP2365811A1 (en) * | 2008-12-12 | 2011-09-21 | Laboratoire HRA Pharma | A method for contraception |
| BRPI1014035A2 (pt) | 2009-04-14 | 2016-04-12 | Hra Pharma Lab | método para contracepção. |
| CN102458386B (zh) * | 2009-06-23 | 2016-04-06 | 拜耳知识产权有限责任公司 | 用于紧急避孕的药物组合物 |
| CN101732324B (zh) * | 2009-12-31 | 2011-12-07 | 广州朗圣药业有限公司 | 一种含有左炔诺孕酮的紧急避孕药物组合物及其制备方法 |
| SG195118A1 (en) | 2011-06-01 | 2013-12-30 | Estetra S A | Process for the production of estetrol intermediates |
| PT2714712T (pt) | 2011-06-01 | 2016-11-08 | Estetra Sprl | Processo para a produção de intermediários de estetrol |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| PL2741824T3 (pl) * | 2011-08-11 | 2018-03-30 | Estetra S.P.R.L. | Zastosowanie estetrolu jako środka antykoncepcji awaryjnej |
| CN104797258A (zh) | 2012-11-22 | 2015-07-22 | 拜耳药业股份公司 | 包含左炔诺孕酮和cox抑制剂的药物组合物用于按需避孕的用途和施用方法 |
| EP2999469A1 (de) | 2013-05-23 | 2016-03-30 | Bayer Pharma Aktiengesellschaft | Pharmazeutische zusammensetzung und deren verwendung sowie anwendungsregime dieser pharmazeutischen zusammensetzung zur bedarfsweisen ( on-demand") kontrazeption |
| CN103877058A (zh) * | 2014-03-26 | 2014-06-25 | 邵娜 | 一种左炔诺孕酮片及其制备工艺 |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| LT3310346T (lt) | 2015-06-18 | 2021-06-10 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| DK3701944T3 (da) | 2015-06-18 | 2022-03-14 | Estetra Srl | Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent |
| CR20180042A (es) | 2015-06-18 | 2018-05-03 | Mithra Pharmaceuticals S A | Unidad de dosificación orodispersable que contiene un componente estetrol. |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| CN111989105B (zh) | 2018-04-19 | 2024-07-19 | 埃斯特拉私人有限责任公司 | 化合物以及它们在缓解绝经相关症状中的用途 |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| CN110917154A (zh) * | 2019-12-12 | 2020-03-27 | 上海信谊天平药业有限公司 | 一种左炔诺孕酮片的制备方法 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022026901A2 (en) * | 2020-07-30 | 2022-02-03 | Acer Therapeutics Inc. | Nk antagonists for contraception |
| CN119523923A (zh) * | 2024-11-21 | 2025-02-28 | 华中药业股份有限公司 | 一种左炔诺孕酮片及其制备方法 |
-
2001
- 2001-11-27 HU HU0105173A patent/HU227198B1/hu unknown
-
2002
- 2002-11-26 NZ NZ530056A patent/NZ530056A/en not_active IP Right Cessation
- 2002-11-26 SI SI200230132T patent/SI1448207T1/xx unknown
- 2002-11-26 EP EP02783334A patent/EP1448207B1/en not_active Expired - Lifetime
- 2002-11-26 PL PL369520A patent/PL206010B1/pl unknown
- 2002-11-26 KR KR1020047002069A patent/KR100908161B1/ko not_active Expired - Lifetime
- 2002-11-26 EA EA200400731A patent/EA006545B1/ru unknown
- 2002-11-26 IL IL15939402A patent/IL159394A0/xx unknown
- 2002-11-26 CN CNA028137523A patent/CN1551774A/zh active Pending
- 2002-11-26 CA CA2450359A patent/CA2450359C/en not_active Expired - Lifetime
- 2002-11-26 ES ES02783334T patent/ES2239727T3/es not_active Expired - Lifetime
- 2002-11-26 PT PT02783334T patent/PT1448207E/pt unknown
- 2002-11-26 AU AU2002347401A patent/AU2002347401A1/en not_active Abandoned
- 2002-11-26 GE GE5567A patent/GEP20063882B/en unknown
- 2002-11-26 MX MXPA04005104A patent/MXPA04005104A/es active IP Right Grant
- 2002-11-26 BR BR0210595-0A patent/BR0210595A/pt not_active Application Discontinuation
- 2002-11-26 AT AT02783334T patent/ATE293978T1/de active
- 2002-11-26 RS YUP-42/04A patent/RS50768B/sr unknown
- 2002-11-26 OA OA1200400148A patent/OA12730A/fr unknown
- 2002-11-26 WO PCT/HU2002/000129 patent/WO2003045397A1/en not_active Ceased
- 2002-11-26 HR HR20040584 patent/HRP20040584B1/xx not_active IP Right Cessation
- 2002-11-26 AP APAP/P/2004/003046A patent/AP1849A/en active
- 2002-11-26 DK DK02783334T patent/DK1448207T3/da active
- 2002-11-26 JP JP2003546899A patent/JP2005516904A/ja not_active Withdrawn
- 2002-11-26 UA UA20040504015A patent/UA79942C2/uk unknown
- 2002-11-26 DE DE60203929T patent/DE60203929T2/de not_active Expired - Lifetime
-
2003
- 2003-12-05 IS IS7065A patent/IS2691B/is unknown
-
2004
- 2004-03-26 TN TNP2004000048A patent/TNSN04048A1/en unknown
- 2004-04-20 NO NO20041607A patent/NO333984B1/no not_active IP Right Cessation
- 2004-04-21 MA MA27643A patent/MA27076A1/fr unknown
- 2004-05-26 ZA ZA2004/04114A patent/ZA200404114B/en unknown
- 2004-06-25 EC EC2004005171A patent/ECSP045171A/es unknown
- 2004-10-05 US US10/495,923 patent/US20050288264A2/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU227198B1 (en) | Pharmaceutical composition for emergency contraception containing levonorgestrel | |
| KR102164693B1 (ko) | 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 | |
| JP2015163646A (ja) | 緊急避妊のための医薬組成物及び処置方法 | |
| JPH1129481A (ja) | 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬 | |
| KR20240047421A (ko) | 자궁내막증 치료 및 효과적인 피임 제공 방법 | |
| JP6254605B2 (ja) | 「オンデマンド」避妊のためのレボノルゲストレルおよびｃｏｘ阻害剤を含む医薬組成物の使用および投与計画 | |
| WO2010007629A1 (en) | A kit comprising anti-emetic and oral contraceptive | |
| US12485128B2 (en) | Progestogen-only oral contraception | |
| KR102210982B1 (ko) | 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 | |
| HK40108056A (zh) | 纯孕激素口服避孕 | |
| HK40111725A (zh) | 治疗子宫内膜异位及提供有效避孕的方法 | |
| HK1070275A (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| Plan et al. | OBG | |
| HK1170686B (en) | Pharmaceutical composition for emergency contraception |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Change of name, address |
Owner name: RICHTER GEDEON NYRT., HU Free format text: FORMER OWNER(S): RICHTER GEDEON VEGYESZETI GYAR RT., HU |